- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Toshiba recruits new director of sales support
Eric Fox has been tapped as the director of sales support, full-line sales, at Toshiba America Medical Systems. Fox will concentrate on managing the department’s overall financial operations, as well as optimizing the quality of TAMS’ sales
Eric Fox has been tapped as the director of sales support, full-line sales, at Toshiba America Medical Systems. Fox will concentrate on managing the department’s overall financial operations, as well as optimizing the quality of TAMS’ sales training program. He will have business and financial responsibilities and will take the lead in designing and implementing sales tools and processes. Fox will also direct continuing development of TAMS’s high-speed data management software system, which serves as the backbone of Toshiba’s 24-hour customer service support center. Before joining Toshiba, Fox was vice president, domestic sales, for I-Flow Corp. Prior to that, he spent 18 years with B. Braun McGaw, formerly a division of American Hospital Supply.
Four Strategies to Address the Tipping Point in Radiology
January 17th 2025In order to flip the script on the impact of the radiology workforce shortage, radiology groups and practices need to make sound investments in technologies and leverage partnerships to mitigate gaps in coverage and maximize workflow efficiencies.
Can Generative AI Facilitate Simulated Contrast Enhancement for Prostate MRI?
January 14th 2025Deep learning synthesis of contrast-enhanced MRI from non-contrast prostate MRI sequences provided an average multiscale structural similarity index of 70 percent with actual contrast-enhanced prostate MRI in external validation testing from newly published research.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
